• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria

tetano

Editor, Senior Moderator
Sci Rep


. 2022 Sep 26;12(1):16001.
doi: 10.1038/s41598-022-20182-y.
Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria


Ilona Bereczki[SUP] #[/SUP][SUP] 1 2 [/SUP], Vladimir Vimberg[SUP] #[/SUP][SUP] 3 [/SUP], Eszter Lőrincz[SUP] 1 4 5 [/SUP], Henrietta Papp[SUP] 2 6 [/SUP], Lajos Nagy[SUP] 7 [/SUP], Sándor Kéki[SUP] 7 [/SUP], Gyula Batta[SUP] 8 [/SUP], Ana Mitrović[SUP] 9 [/SUP], Janko Kos[SUP] 9 10 [/SUP], Áron Zsigmond[SUP] 11 [/SUP], István Hajdú[SUP] 11 [/SUP], Zsolt Lőrincz[SUP] 11 [/SUP], Dávid Bajusz[SUP] 12 [/SUP], László Petri[SUP] 12 [/SUP], Jan Hodek[SUP] 13 [/SUP], Ferenc Jakab[SUP] 2 6 [/SUP], György M Keserű[SUP] 14 [/SUP], Jan Weber[SUP] 13 [/SUP], Lieve Naesens[SUP] 15 [/SUP], Pál Herczegh[SUP] 1 [/SUP], Anikó Borbás[SUP] 16 17 [/SUP]



Affiliations

Abstract

Patients infected with SARS-CoV-2 risk co-infection with Gram-positive bacteria, which severely affects their prognosis. Antimicrobial drugs with dual antiviral and antibacterial activity would be very useful in this setting. Although glycopeptide antibiotics are well-known as strong antibacterial drugs, some of them are also active against RNA viruses like SARS-CoV-2. It has been shown that the antiviral and antibacterial efficacy can be enhanced by synthetic modifications. We here report the synthesis and biological evaluation of seven derivatives of teicoplanin bearing hydrophobic or superbasic side chain. All but one teicoplanin derivatives were effective in inhibiting SARS-CoV-2 replication in VeroE6 cells. One lipophilic and three perfluoroalkyl conjugates showed activity against SARS-CoV-2 in human Calu-3 cells and against HCoV-229E, an endemic human coronavirus, in HEL cells. Pseudovirus entry and enzyme inhibition assays established that the teicoplanin derivatives efficiently prevent the cathepsin-mediated endosomal entry of SARS-CoV-2, with some compounds inhibiting also the TMPRSS2-mediated surface entry route. The teicoplanin derivatives showed good to excellent activity against Gram-positive bacteria resistant to all approved glycopeptide antibiotics, due to their ability to dually bind to the bacterial membrane and cell-wall. To conclude, we identified three perfluoralkyl and one monoguanidine analog of teicoplanin as dual inhibitors of Gram-positive bacteria and SARS-CoV-2.
 
Back
Top Bottom